BTK inhibitor

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

News

Roche chief medical officer Levi Garraway

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

News

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

New data build case for Roche's oral BTK drug for MS

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Data builds on Roche's dominance in primary progressive MS

Sanofi gets double blow for MS drug tolebrutinib

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Lilly eyes earlier use of blood cancer drug Jaypirca

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

BTK inhibitor

Editor's Picks